截断ASXL1突变驱动白血病对T细胞攻击的抵抗力.
bioRxiv : the preprint server for biology
|July 15, 2025
概括
在ASXL1中发生的突变通过抑制白血病中的HLA-I表达来驱动对捐赠淋巴细胞输液 (DLI) 免疫疗法的耐药性. 抑制EZH2可以克服这种免疫逃避,恢复ASXL1-突变瘤中的T细胞杀死.
科学领域:
- 免疫学和癌症生物学
- 分子瘤学分子瘤学
- 遗传学和基因组学 遗传学和基因组学
背景情况:
- 供体淋巴细胞输液 (DLI) 是一种治疗性免疫疗法,用于白血病复发后的异构干细胞移植 (SCT).
- 特定的T细胞子集调解了对DLI的反应,但抵抗机制仍然不完全理解.
- 确定DLI耐药性的遗传驱动因素对于提高治疗疗效至关重要.
研究的目的:
- 确定白血病中的分子通路,使其对DLI免疫疗法产生抗性.
- 调查ASXL1突变在DLI耐药性和免疫逃避中的作用.
- 探索治疗策略来克服ASXL1介导的抗性.
主要方法:
- 在接受DLI治疗的患者中,整体外体和向突变面板测序.
- 单个骨髓细胞转录组学 (scRNA-seq) 和公共数据集的生物信息学分析.
- 基因编辑CRISPR,表观遗传标记分析 (H3K4Me3,H3K27Me3) 和EZH2抑制试验.
- 功能性研究评估CD8+T细胞的识别,激活和杀死.
主要成果:
- 癌源性ASXL1突变 (ASXL1MUT) 被确定为DLI耐药性的遗传基础.
- ASXL1MUT与白血病干细胞转录状态相关,并在髓状恶性瘤中抑制了HLA-I表达.
- ASXL1 校正通过 H3K4Me3 沉积增加了 HLA-I 表达; EZH2 抑制独立于 ASXL1 状态上调了 HLA-I.
- 通过EZH2抑制克服了ASXL1MUT介导的T细胞抑制,恢复了T细胞的死亡.
结论:
- ASXL1突变通过表观遗传变化抑制HLA-I表达来驱动白血病免疫逃避.
- 抑制EZH2是一种潜在的治疗策略,可以绕过ASXL1驱动的免疫抑制.
- 针对ASXL1-HLA-I轴提供了一种新的方法来重新激活T细胞免疫力来对抗ASXL1-突变瘤.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.2K
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
7.7K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
RNA Splicing
57.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.1K
Cancers Originate from Somatic Mutations in a Single Cell
12.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.9K
Loss of Tumor Suppressor Gene Functions
5.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer-Critical Genes II: Tumor Suppressor Genes
8.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.1K
